Cargando…

P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Detalles Bibliográficos
Autores principales:	Dachy, F., Furst, S., Calmels, B., Pagliardini, T., Harbi, S., Bouchacourt, B., Calleja, A., Lemarie, C., Collignon, A., Morel, G., Legrand, F., Bekrieva, E., Granata, A., Weiller, P. J., Chabannon, C., Schiano de Collela, J. M., Vey, N., Blaise, D., Devillier, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430447/ http://dx.doi.org/10.1097/01.HS9.0000848180.08179.b1

Ejemplares similares

P1332: PROMISING OUTCOME OF PATIENTS OLDER THAN 70 YEARS WHO UNDERWENT PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME
por: Harbi, S., et al.
Publicado: (2022)

O-09: DURABLE ENGRAFTMENT AFTER PHARMACOLOGICAL PRE-TRANSPLANT IMMUNOSUPPRESSION FOLLOWED BY REDUCED-TOXICITY MYELOABLATIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN HIGHLY HLA-IMMUNIZED ADULTS WITH SICKLE CELL DISEASE
por: S., FÜRST, et al.
Publicado: (2022)

Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
por: Castagna, Luca, et al.
Publicado: (2020)

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus on Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation
por: El-Cheikh, Jean, et al.
Publicado: (2013)

Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic
por: Mfarrej, B., et al.
Publicado: (2021)

Antithymocyte globulin-induced refractory hypotension in renal transplantation recipient
por: Rafat, Shamim, et al.
Publicado: (2017)

Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation
por: Singh, Namita, et al.
Publicado: (2018)

Tecelac as antithymocyte globulin in conditioning for childhood allogeneic stem cell transplantation
por: Zimmermann, SY, et al.
Publicado: (2002)

Retrospective Evaluation of Rabbit Antithymocyte Globulin Induction in Heart Transplant Patients
por: Lee, Grace Pui-Yun, et al.
Publicado: (2022)

1329. Vancomycin Therapeutic Drug Monitoring: How to hit the Curve
por: Vala, Michael, et al.
Publicado: (2020)

Correction to Lancet Infect Dis 2022; 22: 1329–42
Publicado: (2022)

New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin(®)) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity
por: Mohty, Mohamad, et al.
Publicado: (2014)

Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
por: El-Cheikh, Jean, et al.
Publicado: (2015)

Induction with Rabbit Antithymocyte Globulin following Orthotopic Liver Transplantation for Hepatitis C
por: Saidi, R. F., et al.
Publicado: (2011)

A Review of Induction with Rabbit Antithymocyte Globulin in Pediatric Heart Transplant Recipients
por: Schweiger, Martin, et al.
Publicado: (2018)

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Rabbit Antithymocyte Globulin Induction in Heart Transplant Recipients at High Risk for Rejection
por: Kitto, Brent, et al.
Publicado: (2021)

Erratum to: New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin(®)) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity
por: Mohty, Mohamad, et al.
Publicado: (2014)

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
por: Devillier, Raynier, et al.
Publicado: (2021)

Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications
por: Pourmand, G. R., et al.
Publicado: (2012)

Timing of rabbit antithymocyte globulin induction therapy in kidney transplantation: an observational cohort study
por: Harrison, Jennifer J, et al.
Publicado: (2014)

Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation
por: Yuan, Jiaojiao, et al.
Publicado: (2017)

Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia
por: Kekre, Natasha, et al.
Publicado: (2017)

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

PB1810: OUTCOME OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANT: A SINGLE INSTITUTION RETROSPECTIVE STUDY
por: Castoldi, C., et al.
Publicado: (2022)

Runs 1329 to 1332, 3.5 GeV/c Ring 2
por: Baird, S
Publicado: (1983)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Chronic GVHD: predictive factor for rhinosinusitis in bone marrow transplantation
por: Ortiz, Erica, et al.
Publicado: (2015)

Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD
por: Kostareva, Irina, et al.
Publicado: (2022)

Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
por: Jeong, Rachel, et al.
Publicado: (2020)

1329 Impact of an antimicrobial order auto-stop on clinical outcomes at a single institution
por: Ross, Rachael, et al.
Publicado: (2014)

P1329: REGIONAL COMPARTMENTALIZATION OF THE BONE MARROW STROMA IS IMPORTANT FOR RESPONSES TO INFLAMMATION AND CANCER
por: Swann, James, et al.
Publicado: (2023)

Manufacturing Natural Killer Cells as Medicinal Products
por: Chabannon, Christian, et al.
Publicado: (2016)

A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation
por: Lee, Myung-Won, et al.
Publicado: (2020)

Antithymocyte Globulin Antibody Titer Congruent With Kidney Transplantation: Analysis of Incidence, Outcomes, Cost, and Alternative Targets
por: Lattimore, Sherene, et al.
Publicado: (2019)

Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies
por: Dou, Liping, et al.
Publicado: (2021)

Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHD
por: Shin, Ok S., et al.
Publicado: (2011)

Intestinal aGVHD and infection after hematopoietic stem cell transplantation
por: Hou, Cai-yan, et al.
Publicado: (2013)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ll6bdqmv2e66ccsvpb3a5h7qpn